Giant Cell Tumor of the Extremity

刮除术 医学 骨巨细胞瘤 巨细胞 外科 巨细胞瘤 骨移植 病理
作者
Xiaohui Niu,Qing Zhang,Hao Lin,Yi Ding,Yuan Li,Hairong Xu,Weifeng Liu
出处
期刊:Journal of Bone and Joint Surgery, American Volume [Wolters Kluwer]
卷期号:94 (5): 461-467 被引量:188
标识
DOI:10.2106/jbjs.j.01922
摘要

Background: There are no recent reports of giant cell tumors of bone in a large series of Chinese people. The present study was designed to review the epidemiological characteristics and outcomes of surgical management in a large series of Chinese patients with giant cell tumor of an extremity, treated at a single institution. Methods: The records and images of 621 patients in whom a benign giant cell tumor in an extremity was treated between 1989 and 2009 were reviewed retrospectively. There were 359 male and 262 female patients. The mean age at diagnosis was 31.4 years (range, eleven to seventy-one years). Sixty-six percent of the giant cell tumors were localized around the knee. Surgical treatments primarily included curettage, extensive curettage, and resection. The median duration of follow-up was forty-nine months (range, eighteen to 256 months). Results: Giant cell tumor accounted for 13.7% of all primary bone tumors treated at our institution. Multivariate Cox regression analysis indicated that the only variable that contributed to recurrence-free survival was the type of surgical treatment. The local recurrence rate after extensive curettage was 8.6%, which was significantly lower than the 56.1% recurrence rate after curettage alone. Bone-grafting did not affect local tumor control after extensive curettage; the local recurrence rate was 11.1% if bone graft was used. Recurrent giant cell tumor can be treated by further curettage or resection, with acceptable re-recurrence rates of 6.7% and 9.3% respectively. The Musculoskeletal Tumor Society Score for patients treated with extensive curettage was 92.6%, which was significantly higher than that for patients treated with resection. Twenty-one (3.4%) of the 621 patients developed benign pulmonary metastasis, with a favorable outcome, and three patients presented with multifocal giant cell tumors. Conclusions: The incidence of giant cell tumor in the Chinese population may be higher than that in Western countries, and it has a male predilection. The results of the present study suggest that extensive curettage provides favorable local control and satisfactory functional outcomes. Level of Evidence: Therapeutic Level III. See Instructions for Authors for a complete description of levels of evidence.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
三十四画生完成签到 ,获得积分10
刚刚
耗尽完成签到,获得积分10
2秒前
以戈完成签到,获得积分10
2秒前
cy发布了新的文献求助30
2秒前
leah完成签到 ,获得积分10
2秒前
3秒前
追梦小帅发布了新的文献求助10
4秒前
Akim应助SCL987654321采纳,获得10
6秒前
魏白晴完成签到,获得积分10
7秒前
Haibrar完成签到 ,获得积分10
8秒前
8秒前
IMP完成签到 ,获得积分10
9秒前
吴泽旭发布了新的文献求助10
10秒前
最初的远方完成签到,获得积分10
11秒前
orixero应助rune采纳,获得10
11秒前
zxm完成签到,获得积分10
12秒前
xiaopan9083发布了新的文献求助10
14秒前
赘婿应助猪猪hero采纳,获得10
16秒前
自然方盒完成签到,获得积分10
19秒前
19秒前
RiRi完成签到,获得积分10
20秒前
sunrise_99完成签到,获得积分10
20秒前
俊鱼完成签到,获得积分10
21秒前
翻译度完成签到,获得积分10
23秒前
25秒前
Castiron完成签到 ,获得积分10
25秒前
TT2022发布了新的文献求助10
26秒前
28秒前
52pry发布了新的文献求助10
30秒前
怡然绿兰完成签到,获得积分10
31秒前
utgu完成签到,获得积分10
31秒前
科研通AI5应助cy采纳,获得10
31秒前
HY完成签到 ,获得积分10
33秒前
35秒前
11发布了新的文献求助10
36秒前
36秒前
37秒前
华仔应助rune采纳,获得10
37秒前
38秒前
猪猪hero发布了新的文献求助10
40秒前
高分求助中
【此为提示信息,请勿应助】请按要求发布求助,避免被关 20000
Technologies supporting mass customization of apparel: A pilot project 450
Mixing the elements of mass customisation 360
Периодизация спортивной тренировки. Общая теория и её практическое применение 310
the MD Anderson Surgical Oncology Manual, Seventh Edition 300
Nucleophilic substitution in azasydnone-modified dinitroanisoles 300
Political Ideologies Their Origins and Impact 13th Edition 260
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 物理 生物化学 纳米技术 计算机科学 化学工程 内科学 复合材料 物理化学 电极 遗传学 量子力学 基因 冶金 催化作用
热门帖子
关注 科研通微信公众号,转发送积分 3781132
求助须知:如何正确求助?哪些是违规求助? 3326623
关于积分的说明 10227813
捐赠科研通 3041744
什么是DOI,文献DOI怎么找? 1669585
邀请新用户注册赠送积分活动 799104
科研通“疑难数据库(出版商)”最低求助积分说明 758751